NCT02843126View on ClinicalTrials.gov

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2019

Conditions
Recurrent Breast Cancer
Interventions
DRUG

Trastuzumab

Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)

BIOLOGICAL

NK immunotherapy

For each procedure, 10 billion cells will be infused for 4 times

Trial Locations (1)

510000

Fuda cancer institute in Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02843126 - Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer | Biotech Hunter | Biotech Hunter